Seeking Alpha: Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
Nasdaq: Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025
Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025
Florida Today: Focus on Eyes: Cloudy eyes, discomfort could be symptoms of Fuchs' dystrophy
In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a condition in the cornea that subsequently bears his name. The patients ...
Focus on Eyes: Cloudy eyes, discomfort could be symptoms of Fuchs' dystrophy
CARLSBAD, Calif., (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...
Yes. Treatments for substance use disorders can help a person stop or reduce their drug use, help prevent a return to use (relapse), alleviate the negative consequences associated with their drug use, and help them regain the ability to function successfully at work, in their family, and in their community.
Can addiction be treated successfully? Yes, addiction is a treatable disorder. Research on the science of addiction and the treatment of substance use disorders has led to the development of research-based methods that help people to stop using drugs and resume productive lives, also known as being in recovery. Can addiction be cured? Like treatment for other chronic diseases such as heart ...